Harneet Kaur
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Harneet Kaur has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Annie Berkley
Takeda UK Ltd, London, UK
2 shared publications - Amie Padhiar
Takeda UK Ltd, London, UK
1 shared publication - Colin Burke
Lumanity, London, UK
1 shared publication Debjit Ghoshal
Lumanity, Gurugram, India
1 shared publicationHarold Wolff
Lumanity, Sheffield, UK
1 shared publicationInderpreet Singh Khurana
Lumanity, Gurugram, India
1 shared publication
Latest Publications
- Open Access
- 28 May 2026
- Published by Taylor & Francis in Expert Review of Hematology
- Vol. 19 (7) , 757-765
ADAMTS13 activity and clinical outcomes: a targeted literature review in congenital thrombotic thrombocytopenic purpura and other related thrombotic conditions
1. ADAMTS13 (a disintegrin and metalloproteinase with thrombospondin motifs 13) is a plasma protease that plays a key role in hemostasis by cleaving ultra-large von Willebrand factor (VWF) multimer...
- 28 May 2026
- Published by Taylor & Francis in Expert Review of Hematology
- Vol. 19 (7) , 757-765
Open AccessADAMTS13 activity and clinical outcomes: a targeted literature review in congenital thrombotic thrombocytopenic purpura and other related thrombotic conditions
1. ADAMTS13 (a disintegrin and metalloproteinase with thrombospondin motifs 13) is a plasma protease that plays a key role in hemostasis by cleaving ultra-large von Willebrand factor (VWF) multimer...
- Open Access
- 1 March 2026
- Published by Taylor & Francis in Journal of Blood Medicine
- Vol. ume 17, 1-16
Systematic Literature Review of the Economic and Quality of Life Burden of Congenital and Immune-Mediated Thrombotic Thrombocytopenic Purpura
Background: Thrombotic thrombocytopenic purpura (TTP) is a life-threatening blood disorder resulting from ADAMTS13 deficiency, caused by mutations in the ADAMTS13 gene in congenital TTP (cTTP), and by neutralizing antibodies against ADAMTS13 in immune-mediated TTP (iTTP). This systematic review summarizes available economic evaluations, healthcare resource utilization (HCRU), cost, utility, and health-related quality of life (HRQoL) literature in TTP, with a focus on cTTP. Given the limited availability of cTTP-specific data, broader TTP evidence was also reviewed to infer potential implications for cTTP where appropriate. Methods: Three systematic literature searches were conducted in January 2024 in accordance with PRISMA guidelines, each tailored to identify studies reporting economic evaluations, HCRU/cost data, and utility/HRQoL data respectively. For the economic evaluation and utility/HRQoL reviews, inclusion criteria were broadened to include studies reporting data on iTTP and unspecified TTP from which findings for cTTP were inferred. Results: In total 431, 989, and 849 records were identified for the economic evaluation, HCRU/cost, and utility/HRQoL reviews, respectively. No economic evaluations were identified for treatments in cTTP populations. Eight economic studies (all in iTTP) were included. Overall, 5 studies found caplacizumab to be cost-effective, whereas 3 did not, highlighting variability across model assumptions and healthcare settings. Six HCRU/cost studies reported that cTTP was associated with frequent hospital interactions, missed work time, and high costs. Fourteen studies (1 in cTTP, 10 in iTTP, and 3 in unspecified TTP) were included in the utility/HRQoL review and showed that TTP is associated with reduced utility scores and lower HRQoL, irrespective of TTP subtype. Conclusion: These findings underscore the meaningful patient burden observed across the TTP spectrum and highlight the need for further research to evaluate the cost-effectiveness of emerging therapies in cTTP. However, the predominance of iTTP data reflects ongoing challenges in evidence generation for rare TTP subtypes such as cTTP.
- 1 March 2026
- Published by Taylor & Francis in Journal of Blood Medicine
- Vol. ume 17, 1-16
Open AccessSystematic Literature Review of the Economic and Quality of Life Burden of Congenital and Immune-Mediated Thrombotic Thrombocytopenic Purpura
Background: Thrombotic thrombocytopenic purpura (TTP) is a life-threatening blood disorder resulting from ADAMTS13 deficiency, caused by mutations in the ADAMTS13 gene in congenital TTP (cTTP), and by neutralizing antibodies against ADAMTS13 in immune-mediated TTP (iTTP). This systematic review summarizes available economic evaluations, healthcare resource utilization (HCRU), cost, utility, and health-related quality of life (HRQoL) literature in TTP, with a focus on cTTP. Given the limited availability of cTTP-specific data, broader TTP evidence was also reviewed to infer potential implications for cTTP where appropriate. Methods: Three systematic literature searches were conducted in January 2024 in accordance with PRISMA guidelines, each tailored to identify studies reporting economic evaluations, HCRU/cost data, and utility/HRQoL data respectively. For the economic evaluation and utility/HRQoL reviews, inclusion criteria were broadened to include studies reporting data on iTTP and unspecified TTP from which findings for cTTP were inferred. Results: In total 431, 989, and 849 records were identified for the economic evaluation, HCRU/cost, and utility/HRQoL reviews, respectively. No economic evaluations were identified for treatments in cTTP populations. Eight economic studies (all in iTTP) were included. Overall, 5 studies found caplacizumab to be cost-effective, whereas 3 did not, highlighting variability across model assumptions and healthcare settings. Six HCRU/cost studies reported that cTTP was associated with frequent hospital interactions, missed work time, and high costs. Fourteen studies (1 in cTTP, 10 in iTTP, and 3 in unspecified TTP) were included in the utility/HRQoL review and showed that TTP is associated with reduced utility scores and lower HRQoL, irrespective of TTP subtype. Conclusion: These findings underscore the meaningful patient burden observed across the TTP spectrum and highlight the need for further research to evaluate the cost-effectiveness of emerging therapies in cTTP. However, the predominance of iTTP data reflects ongoing challenges in evidence generation for rare TTP subtypes such as cTTP.